Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.89 USD | +1.23% | -16.71% | -9.97% |
Sales 2024 * | 42.75K 3.42M | Sales 2025 * | 4.12M 330M | Capitalization | 493M 39.5B |
---|---|---|---|---|---|
Net income 2024 * | -283M -22.65B | Net income 2025 * | -305M -24.42B | EV / Sales 2024 * | 5,693 x |
Net cash position 2024 * | 250M 20.01B | Net cash position 2025 * | 284M 22.73B | EV / Sales 2025 * | 50.9 x |
P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-1.74
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.82% |
Latest transcript on Allogene Therapeutics, Inc.
1 day | +1.23% | ||
1 week | -16.71% | ||
Current month | -35.35% | ||
1 month | -31.35% | ||
3 months | -10.80% | ||
6 months | +9.47% | ||
Current year | -9.97% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 31/10/17 |
David Chang
FOU | Founder | 64 | 31/03/18 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 15/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 30/04/18 |
Joshua Kazam
FOU | Founder | 47 | 31/10/17 |
Arie Belldegrun
FOU | Founder | 74 | 31/10/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.54% | 2 M€ | -25.75% | ||
0.08% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 2.89 | +1.23% | 2,452,436 |
25/04/24 | 2.855 | -6.09% | 2,772,870 |
24/04/24 | 3.04 | -9.79% | 2,108,440 |
23/04/24 | 3.37 | -0.88% | 1,606,762 |
22/04/24 | 3.4 | -2.02% | 1,789,993 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.97% | 493M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALLO Stock